GERON CORP
GERNNASDAQπ #2675 by market capUS Equity
$0.87βΌ $0.04 (β4.88%)
Market closed Β· at closeTrack GERN
Get earnings, price moves & breaking news on Telegram
24hβΌ 4.9%
7dβ
14dβ
30dβ
ytdβ
1yβ
π¦Market Cap
$558M
Small Cap
πRevenue Growth (YoY)
18.6%
Healthy
πGross Margin
96.7%
High
π΅FCF Margin
4.6%
Moderate
βοΈP/S Ratio
2.7x
Cheap
Otter Score
72
Strong
No chart data available for GERN.
Trading Snapshot
- Day Range
- $0.86 β $0.92
- 52-Week Range
- $0.84 β $2.01
- Volume (shares)
- 300,278
- Avg Volume (shares)
- β
- Shares Outstanding
- 642.5M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $184M
- Last Q Revenue
- $60M
- P/E Ratio
- β
- P/S Ratio
- 2.7x
- EPS (TTM)
- $-0.07
- Dividend Yield
- β
- Dilution (1yr)
- +3.3%
GERON CORP
GERNFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$184Mβ² +138.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.4%βΌ β1.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$54MβΌ β69.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$111MβΌ β49.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
667.2Mβ² +3.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
β$172MβΌ β$129M YoY
About GERON CORP
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Strong
72/100
Analyst data unavailable.
Latest News & Updates
News unavailable.